ArticleAnnals of medicine2025
Integrating systemic inflammation and liver biomarkers: prognostic implications of the ferritin index in heart failure.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence and Clinical Correlates of Iron Deficiency in Vietnamese Patients with Chronic Heart Failure.Biomedicines · 2026Article
- Response to letter regarding "integrating systemic inflammation and liver biomarkers:prognostic implications of the ferritin index in heart failure".Annals of medicine · 2025Article
- Comment on 'integrating systemic inflammation and liver biomarkers: prognostic implications of the ferritin index in heart failure'.Annals of medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is increasingly recognized as a multisystem syndrome involving systemic inflammation and metabolic dysfunction in addition to cardiac and hepatic impairment. Traditional liver fibrosis scores, such as the fibrosis-4 (FIB-4) index, focus solely on hepatic injury and may underestimate the broader systemic burden. The ferritin index, which adjusts serum ferritin for age and sex, may better reflect inflammatory and metabolic dysregulation, including features of metabolic hyperferritinaemia. This study aimed to evaluate the prognostic value of the ferritin index versus the FIB-4 score in predicting major adverse cardiovascular events (MACE) in patients with HF. MATERIALS AND
methodsThis retrospective cohort study included 751 HF patients from the Changhua Christian Hospital Clinical Research Database, spanning all ejection fraction categories. Cox regression models were used to assess associations between MACE and tertiles of ferritin index and FIB-4 score, with adjustments for baseline characteristics.
resultsPatients in the highest ferritin index tertile had significantly increased MACE risk (adjusted hazard ratio 1.92;
conclusionThe ferritin index outperforms the FIB-4 score in predicting MACE in HF patients. By integrating systemic inflammatory and metabolic signals, it improves risk stratification, especially in those with features of metabolic hyperferritinaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.